Jyong Biotech Ltd. (MENS) Stock Price, Quote & News

Company Profile

Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.

Industry: Biotechnology

Sector: Healthcare

Phone: 886 2 2732 5205

Website: jyongbio.com

Address:

No. 95, Xintai 5th Road, 23F-3 Section 1 Xizhi District, New Taipei City, Taiwan

aquira Mar. 20 at 2:53 PM

$MENS 3 weeks ago I was green now I'm 40% in the red. Fucking hell. Should i sell and just move on?

1 · Reply

Everythingisplanned Mar. 18 at 5:50 PM

$MENS so quiet! Hopefully some news unfolds soon....

0 · Reply

aquira Mar. 16 at 4:12 PM

$MENS what the heckkkk guysssss

0 · Reply

aquira Mar. 13 at 6:37 PM

$MENS fooockeeennn shiteee man! Back to $1 land again. Fooocccckkkkkkkkkk

0 · Reply

Everythingisplanned Mar. 11 at 7:36 PM

$MENS what just happened 🙈!

0 · Reply

Everythingisplanned Mar. 11 at 1:49 PM

$MENS

0 · Reply

peepthestamp Mar. 9 at 8:33 PM

$MENS -Aging Well 🫡

0 · Reply

Everythingisplanned Mar. 4 at 5:59 PM

$MENS LFG!!

0 · Reply

1_ofThe_orig_Moonboyz Mar. 3 at 12:28 PM

$MENS Don’t beat your head against a wall here. When you can enjoy EONR

0 · Reply

aquira Mar. 2 at 8:31 PM

$MENS come on!!!!

0 · Reply

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jan 30, 2026, 8:30 AM EST - 7 weeks ago

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Dec 19, 2025, 9:00 AM EST - 3 months ago

Jyong Biotech Responds to Share Price and Volume Movement

Dec 4, 2025, 8:30 AM EST - 3 months ago

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Nov 24, 2025, 8:30 AM EST - 4 months ago

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Nov 20, 2025, 8:30 AM EST - 4 months ago

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Sep 29, 2025, 8:30 AM EDT - 6 months ago

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards

Sep 18, 2025, 8:30 AM EDT - 6 months ago

Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei

Sep 16, 2025, 8:18 AM EDT - 6 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Aug 22, 2025, 9:00 AM EDT - 7 months ago

Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP)

Jul 26, 2025, 8:00 AM EDT - 8 months ago

Jyong Biotech's Plant‑Based Pipeline Targets Huge Markets But Risks Remain

Jul 22, 2025, 10:40 AM EDT - 8 months ago

Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention

Jun 22, 2025, 4:20 PM EDT - 9 months ago

U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million

ALAB ARM CAI EGG IPO IPOS JCAP

Jun 18, 2025, 5:20 PM EDT - 9 months ago

Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering

Jun 16, 2025, 11:38 PM EDT - 9 months ago

Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering

Feb 10, 2025, 3:42 PM EST - 1 year ago

Jyong Biotech Seeks US IPO On Thin Capitalization And Uphill Regulatory Battle

Aug 18, 2023, 2:44 PM EDT - 2 years ago

Jyong Biotech Ltd. Begins U.S. IPO Rollout

Aug 17, 2023, 3:16 PM EDT - 2 years ago

Urinary disease biotech Jyong Biotech files for a $40 million US IPO

Aug 17, 2023, 1:40 PM EDT - 2 years ago

Jyong Biotech IPO Registration Document (F-1)

aquira Mar. 20 at 2:53 PM

$MENS 3 weeks ago I was green now I'm 40% in the red. Fucking hell. Should i sell and just move on?

1 · Reply

Everythingisplanned Mar. 18 at 5:50 PM

$MENS so quiet! Hopefully some news unfolds soon....

0 · Reply

aquira Mar. 16 at 4:12 PM

$MENS what the heckkkk guysssss

0 · Reply

aquira Mar. 13 at 6:37 PM

$MENS fooockeeennn shiteee man! Back to $1 land again. Fooocccckkkkkkkkkk

0 · Reply

Everythingisplanned Mar. 11 at 7:36 PM

$MENS what just happened 🙈!

0 · Reply

Everythingisplanned Mar. 11 at 1:49 PM

$MENS

0 · Reply

peepthestamp Mar. 9 at 8:33 PM

$MENS -Aging Well 🫡

0 · Reply

Everythingisplanned Mar. 4 at 5:59 PM

$MENS LFG!!

0 · Reply

1_ofThe_orig_Moonboyz Mar. 3 at 12:28 PM

$MENS Don’t beat your head against a wall here. When you can enjoy EONR

0 · Reply

aquira Mar. 2 at 8:31 PM

$MENS come on!!!!

0 · Reply

Everythingisplanned Mar. 2 at 4:51 PM

$MENS News should push this!! Otherwise this is a daily play

0 · Reply

brisius Mar. 2 at 3:02 PM

$MENS we have news?

1 · Reply

Everythingisplanned Feb. 27 at 5:43 PM

$MENS

1 · Reply

aquira Feb. 27 at 5:32 PM

$MENS fuckkkk are we fooking going back to 1s???? Grrrr this is making me maddds

0 · Reply

aquira Feb. 27 at 4:25 PM

$MENS come on!!!!

0 · Reply

aquira Feb. 25 at 3:17 PM

$MENS fuckkkkk why the huge drop

0 · Reply

Everythingisplanned Feb. 24 at 5:46 PM

$MENS

1 · Reply

IntraTrades Feb. 23 at 11:16 PM

$KLTO 57.75% $CETY 45.40% $YMAT 41.19% $MENS 35.82% $GFAI 35.80%

0 · Reply

topstockalerts Feb. 23 at 9:23 PM

Top Gainers PT2 $VNDA $INVZW $CETY $MENS $ASPS

0 · Reply

topstockalerts Feb. 23 at 8:53 PM

$MENS can it push higher in AH?

0 · Reply

Stackdoe101 Feb. 23 at 8:51 PM

$MENS

0 · Reply

char13 Feb. 23 at 8:37 PM

$MENS another runner that seems to be surprising

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,440,831
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A